Article Text

Download PDFPDF
CASE REPORT
Revisiting propafenone toxicity
  1. Ali A Alsaad1,
  2. Yahaira Ortiz Gonzalez2,
  3. Christopher O Austin2,
  4. Fred Kusumoto2
  1. 1 Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA
  2. 2 Department of Cardiovascular Diseases, Mayo Clinic Florida, Jacksonville, Florida, USA
  1. Correspondence to Dr Ali A Alsaad, alsaad.ali{at}mayo.edu

Summary

Propafenone is a Vaughan Williams class 1c antiarrhythmic medication widely used for treatment of arrhythmias. Although the long-term safety of propafenone use has not been established, it is commonly used for treatment of atrial fibrillation in patients with no structural heart disease. Propafenone is well known as pill-in-the-pocket treatment for its effect in terminating paroxysmal episodes of atrial fibrillation. Herein, we discuss an unusual adverse reaction to propafenone in a patient who presented with symptomatic bradycardia and hypotension. The aim of this article is to increase physician awareness for propafenone toxicity and its management, with a focused literature review on propafenone pharmacotherapy.

  • Cardiovascular medicine
  • Pacing and electrophysiology
  • Drug interactions

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors AAA authored the manuscript, designed the figures and conducted the literature review. YOG and COA interpreted the figures and reviewed the manuscript. FK carefully reviewed the manuscript. All authors approved the manuscript prior to submission.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.